Antifungal Therapy
Antifungal therapy still guided empirically due to lack of human data
Published in Blood Weekly, September 16th, 2004
According to recent research published in the British Journal of Haematology, "The availability of new antifungal agents with unique mechanisms of action and improved tolerability has widened the possibilities for the use of combination antifungal therapy for difficult-to-treat opportunistic mycoses.
"However, the use of this therapy is largely governed by empiricism, especially in patients with invasive mould infections, for whom there is a tremendous need to improve outcomes."
"Because of the difficulties associated with the design and conduct...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2004-09-16)
More Articles from Blood Weekly
- Coagulation Therapy
Traditional anticoagulants pose problems; Fondaparinux represents improvement - Hemophilia A
Pharma company launches 2005 cycle for hemophilia awards program - Sepsis
Extracorporeal device efficiently removes endotoxin from whole blood - Stem Cell Research
CD8-deplted donor cell infusions effective for treatment of SCT relapse - Stem Cell Research
Mesenchymal stem cells feasible for intervertebral disc regeneration - Angiology
Activated protein C maintains vascular integrity by stimulating angiogenesis - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
